1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
CellaVision AB (publ)

CellaVision AB (publ)

CEVI.ST
CellaVision AB (publ)SE flagStockholm Stock Exchange
143.40
SEK
-3.00
- -
3.42BMarket Cap
CellaVision AB (publ)
CEVI.ST
(Stockholm Stock Exchange)

Recent

price

143.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.52
6.52
7.11
7.54
9.09
10.04
11.11
12.97
15.29
19.36
19.77
23.71
26.8
28.4
30.32
31.82
30.63
Revenue per Share
1.61
0.61
0.27
0.79
1.32
2.21
2.51
2.92
3.72
4.16
3.75
5.25
4.96
5.46
5.9
6.42
5.62
Basic EPS, GAAP
0.47
1.09
0.02
0.65
1.09
3.3
2.57
2.47
2.92
5.17
2.64
6.7
5.76
8.24
8.32
8.41
8.45
Free Cash Flow per Basic Share
- -
0.21
0.4
0.4
0.5
1
1.5
1.5
1.5
1.5
- -
0.75
2
2.25
2.25
2.5
2.5
Dividend per Share
4.2
4.82
4.69
5.08
5.9
7.11
8.12
9.54
11.76
14.42
18.17
22.68
25.64
28.85
32.5
36.42
- -
Book Value per Share
4.76
4.39
4.22
4.45
5.2
6.46
7.19
7.85
9.33
2.04
5.4
7.76
10.16
11.87
13.75
15.04
15.77
Tangible Book Value per Share
24
24
24
24
24
24
24
24
24
24
24
24
24
24
24
24
24
Basic Weighted Avg Shares
132
155
170
180
217
239
265
309
365
462
471
566
639
677
723
759
731
Sales/Revenue/Turnover
10.6
11.45
12.21
14.43
19.74
27.35
27.98
29.39
30.59
27.41
23.39
28.77
24.75
24.66
24.57
26.62
23.74
Operating Margin (%)
- -
6
8
9
13
8
8
8
7
20
32
33
40
40
41
40
- -
Depreciation Expense
38
15
6
19
31
53
60
70
89
99
89
125
118
130
141
153
134
Net Income, GAAP
- -
20.96
65.23
23.32
27.45
19.42
21.08
22.82
20.88
23.25
20.27
20.82
20.28
20.65
20.43
21.2
21.25
Effective Tax Rate (%)
29.13
9.42
3.81
10.53
14.51
22.07
22.56
22.54
24.31
21.48
18.98
22.16
18.51
19.24
19.46
20.17
18.35
Profit Margin (%)
36
53
60
70
98
140
167
188
223
139
194
230
244
246
294
330
348
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
123
87
96
60
29
13
12
10
LT Debt
113
126
125
133
151
184
206
241
290
348
430
543
642
716
816
888
914
Total Equity
- -
10.05
5.12
13.64
20.13
30.97
29.68
31.02
32.85
23.69
16.17
20.7
17.69
17.37
17.41
18.14
15.19
Return on Invested Capital (%)
- -
11.7
5.17
14.36
22.22
33.4
32.49
32.73
34.52
24.99
16.89
20.39
17.28
18.12
18.29
18.13
611.39
Return on Capital (%)
47.32
13.61
5.69
16.26
24.03
34.04
32.92
33.1
34.91
31.76
23.02
25.73
20.54
20.05
19.23
18.62
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
14
14
12
LT Borrowings
13
12
10
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
24
Market Capitalization
4,117
3,749
3,664

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
426
441
472
Cash, Cash Equivalents & STI
159
188
230
Accounts Receivable, Net
130
120
91
Inventories
113
112
122
Total Current Liabilities
129
111
124
Payables & Accruals
- -
- -
- -
ST Debt
14
14
12
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.19%
15.78%
8.81%
Free Cash Flow
20.5%
36.94%
1.06%
Net Income, GAAP
12.04%
12.27%
8.78%
Sales/Revenue/Turnover
12.47%
10.13%
4.94%
Total Cash Common Dividend
- -
- -
11.11%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
170
188
179
187
723
2025
195
191
176
197
759
2026
166
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.26
1.62
1.3
1.72
5.9
2025
1.74
1.58
1.31
1.79
6.42
2026
0.94
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
2.25
- -
- -
2.25
2025
- -
2.5
- -
- -
2.5
2026
- -
- -
- -
- -
- -
Similar Companies
SeaSpine Holdings Corporation (SPNE)
DongBang Medical (240550.KQ)
Positron Corporation (POSC)
CVRx, Inc. (CVRX)
Getinge AB (publ) (GNGBY)
Aurora Spine Corporation (ASG.V)
Business
CellaVision AB (publ) (CEVI.ST) develops and markets digital hematology microscopy solutions that automate the analysis of blood and body fluid samples for laboratories worldwide; core products include advanced analyzers such as the DI-60 for high-throughput large labs and the DC-1 compact system for small and medium-sized facilities, reagents encompassing staining protocols, smear makers and stainers like RAL SmearBox and RAL StainBox, and software platforms for image analysis, remote access, competency testing, and artificial intelligence-driven cell classification. The company manufactures reagents in-house at its facility in Martillac, France, with analyzer production outsourced in Sweden. Founded in 1994 and headquartered in Lund, Sweden, CellaVision employs over 230 staff, maintains market support offices in 16 countries including the US, Canada, Japan, China, and several European and Asian markets, and serves over 40 countries through global partners, targeting healthcare providers handling human and veterinary samples. CellaVision integrates hardware, software, and consumables into a recurring revenue model bolstered by its 2019 acquisition of RAL Diagnostics, which expanded sample preparation capabilities in hematology, microbiology, cytology, and pathology while adding vertical integration for quality control and new revenue streams. In 2024, the company marked 30 years of operations with sales reaching SEK 723 million and reported 14% organic growth in Q1 2025 driven by instrument sales in EMEA, alongside ongoing expansions like enhanced alliances such as with Sysmex Corporation to advance diagnostic technologies. Recent activities include the May 2025 Annual General Meeting approving a SEK 2.50 per share dividend, board re-elections, and share repurchase authorizations, reflecting sustained strategic focus on innovation and market penetration.